Citations

Clear

16280 citation(s) found for "Yu, David".

MBOAT7 encephalopathy: Characterizing the neurology and epileptology
Ortiz, Sebastian , Rizzo, Viviana , Bartolomaeus, Tobias , Escolar, Maria L. , Gavrilova, Ralitza, Ahrens‐Nicklas, Rebecca C. , Boycott, Kym M. , Costa, Cinzia , Rakić, Bojana , Huynh, Stephanie, Huh, Linda , Sherr, Elliott H. , Ortigoza‐Escobar, Juan Darío , Casas‐Alba, Dídac , Nunes, Tania, Koolen, David A. , Khinchi, Marianne Søndergaard, Møller, Rikke S. , Bayat, Allan , Rizzo, Valentina , Costa, Cinzia , Platzer, Konrad , Gardella, Elena , Møller, Rikke S , Bayat, Allan , Jauss, Robin‐Tobias , Bernard, Geneviève , Lemire, Gabrielle , Mercimek‐Andrews, Saadet , Prontera, Paolo , Boerkoel, Cornelius F. , Argilli, Emanuela , Platzer, Konrad , Gardella, Elena , Fenger, Christina

Mayo Clinic

Epilepsia | March 23, 2025 | Volume: 66 | Issue: 7 | Pages: 2379-2390

10.1111/epi.18376 | PMID 40116760 Get It

Abstract Objective Biallelic pathogenic MBOAT7 variants are associated with neurodevelopmental disorders, intellectual disability (ID), epilepsy, and neuropsychiatric disorders such as attention‐deficit/hyperactivity disorder and autism spectrum disorders. We aimed to characterize the epilepsy phenotype in a cohort of patients affected by this syndrome. Methods We describe epilepsy features, electroencephalography, magnetic resonance imaging (MRI) findings, antiseizure treatment response, and neurodevelopment of 15 patients with biallelic MBOAT7 variants. Results All 15 patients had ID or developmental delay (DD). Twelve suffered from epilepsy, with mean age at seizure onset of 36 months (range = 2 months–6.5 years) and 10 of 12 showing signs of DD before seizure onset. Patients with epilepsy presented with focal motor seizures with impaired awareness ( n = 3), focal tonic–clonic seizures and epileptic spasms ( n = 1), focal to bilateral tonic–clonic seizures ( n = 1), unknown onset bilateral tonic–clonic seizures ( n = 2), myoclonic seizures ( n = 4), myoclonic–atonic seizures ( n = 1), atonic seizures ( n = 1), tonic seizures ( n = 1), and myoclonic absences ( n = 2). Seizure freedom was achieved in 66.7% (8/12), with variable antiseizure treatment regimes. We reviewed electroencephalograms of the patients with epilepsy. Background activity was normal in 64%, whereas 36% had either a generalized or a focal slowing. Interictal epileptiform discharges (IEDs) were reported in 83%. Generalized spikes/polyspikes were found in 53%, multifocal IEDs in 23%, and parasagittal focal IEDs in 26%. The most frequent abnormal brain MRI findings, reported in 58% of patients, included high‐intensity signal in T2 and fluid‐attenuated inversion recovery (FLAIR) sequences in dentate nuclei and globus pallidus. Biallelic missense variants seemed to be associated with better cognitive and motor outcomes compared to truncating variants and in‐frame deletions. Significance Biallelic MBOAT7 variants are associated with global developmental impairment in all affected patients and epilepsy in the majority. The seizure semiology is heterogenous. One third of our cohort had persistent seizures despite treatment. The most frequent MRI findings were hyperintensities in T2/FLAIR sequences in dentate nuclei and globus pallidus.
Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
Demmer, Ryan T. , Wu, Christina , Sun, Yifei , Cushman, Mary , Boyle, Rebekah, Styer, Linda M. , Bell, Taison D., Anderson, Michaela R. , Schreiner, Pamela J. , Bowler, Russell, Rock, Jean M., Bievenue, Rachel, Kandula, Namratha R. , Raffield, Laura M. , Elkind, Mitchell S.V. , Ortega, Victor E. , Woodruff, Prescott G. , Oelsner, Elizabeth C. , Wu, Chaoqi , Anderson, Michaela R , Lee, Joyce S , Xanthakis, Vanessa , Pirzada, Amber , Mantis, Nicholas J , Raffield, Laura M , Oelsner, Elizabeth C , Demmer, Ryan T , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Doyle, Margaret F. , Regan, Elizabeth Anne , Make, Barry J. , Kanaya, Alka M , Wenzel, Sally E. , Coresh, Josef , Isasi, Carmen R. , Howard, Virginia J. , Cole, Shelley A. , Henderson, Joel

Mayo Clinic

Open Forum Infectious Diseases | March 20, 2025 | Volume: 12 | Issue: 3 | Pages: No page available

10.1093/ofid/ofaf123 | PMID 40124199 Get It

Abstract Despite the availability of effective vaccines and a recent decrease in annual deaths, COVID-19 remains a leading cause of death. Serological studies provide insights into host immunobiology of adaptive immune response to infection, which holds promise for identifying high-risk individuals for adverse COVID-19 outcomes. We investigated correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults participating in longstanding National Institutes of Health–funded cohort studies. Anti-nucleocapsid antibodies were measured from dried blood spots collected between February 2021 and February 2023. Among 1419 Collaborative Cohort of Cohorts for COVID-19 Research participants with prior SARS-CoV-2 infection, the mean age (standard deviation) was 65.8 (12.1), 61% were women, and 42.8% self-reported membership in a race/ethnicity minority group. The proportion of participants reactive to nucleocapsid peaked at 69% by 4 months after infection and waned to only 44% ≥12 months after infection. Higher anti-nucleocapsid antibody response was associated with older age, Hispanic or American Indian Alaskan Native (vs White) race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels. Asian race (vs White) and vaccination (even after infection) were associated with lower nucleocapsid reactivity. Neither vaccine manufacturer nor common cardiometabolic comorbidities were not associated with anti-nucleocapsid response. These findings inform the underlying immunobiology of adaptive immune response to infection, as well as the potential utility of anti-nucleocapsid antibody response for clinical practice and COVID-19 serosurveillance.
Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma
Ran, Nina A., Granger, Emily , Brodland, David G., Cañueto, Javier , Carr, David R., Carter, Joi B., Hirotsu, Kelsey E. , Koyfman, Shlomo A. , Mangold, Aaron R. , Girardi, Fábio Muradás , Shahwan, Kathryn T. , Vidimos, Allison T. , Willenbrink, Tyler J., Wysong, Ashley, Ruiz, Emily S. , Mangold, A R , Granger, Emily E., Carucci, John A. , Srivastava, Divya , Wysong, Ashley

Mayo Clinic

JAMA Dermatology | March 19, 2025 | Volume: 161 | Issue: 6 | Pages: 597

10.1001/jamadermatol.2025.0128 | PMID 40105853 Get It

ImportanceCutaneous squamous cell carcinoma (CSCC) risk stratification is central to management, and physicians rely on tumor staging systems to estimate risk. The Brigham and Women’s Hospital (BWH) T staging system predicts risk based on 4 tumor risk factors (RFs). However, stage is not precisely associated with the number of RFs, as BWH stage T2b includes CSCCs with 2 and 3 RFs.ObjectiveTo determine how RF number is associated with the risk of recurrence, metastasis, and disease-related death.Design, Setting, and ParticipantsThis retrospective multination cohort study of CSCCs diagnosed between October 1, 1991, and July 19, 2023, was conducted at 12 centers in the US (10), Spain (1), and Brazil (1). Invasive CSCCs with confirmed negative margins longer than 14 days were included. Tumors were excluded if they were metastatic at presentation or received adjuvant therapy. Data were analyzed from October 2023 to August 2024.Interventions or ExposuresCSCCs were stratified by the number of the following RFs (0, 1, 2, 3, or 4): a diameter of 2 cm or larger, poorly differentiated histology, tumor extension beyond subcutaneous fat, and large caliber nerve invasion.Main Outcomes and MeasuresFive-year cumulative incidences of local recurrence, nodal metastasis, distant metastasis, and disease-specific death.ResultsA total of 16 844 CSCCs were included (5978 female individuals [35.5%]; median [IQR] age, 73.9 [65.7-81.8] years), with 0 (12 657 [75.1%]), 1 (2892 [17.2%]), 2 (1015 [6.0%]), 3 ( 225 [1.3%]) or 4 (55 [0.3%]) RFs. Median (IQ) follow up time was 33.6 (14.5-60.3) months. For local recurrence, the risk increased as the number of RF increased from 0 (1.7%; 95% CI, 1.5%-2.0%) to 1 (5.0%; 95% CI, 4.1%-5.9%) to 2 (8.8%; 95% CI, 7.0%-11.0%) to 3 (16.0%; 95% CI, 11.0%-22.0%) to 4 (33.0%; 95% CI, 19.0%-47.0%; P < .001 for between-group differences). This increase was also observed for nodal metastasis (0.6% [95% CI, 0.4%-0.7%] vs 3.6% [95% CI, 2.9%-4.4%] vs 11.0% [95% CI, 9.2%-13.0%] vs 20.0% [95% CI, 15.0%-26.0%] vs 28.0% [95% CI, 15.0%-42.0%], respectively; P < .001), distant metastasis (0.2% [95% CI, 0.1%-0.3%] vs 1.1% [95% CI, 0.7%-1.6%] vs 2.3% [95% CI, 1.4%-3.4%] vs 7.9% [95% CI, 4.6%-12.0%] vs 8.4% [95% CI, 2.6%-19.0%], respectively; P < .001), and disease-specific death (0.3% [95% CI, 0.2%-0.4%] vs 1.9% [95% CI, 1.4%-2.7%] vs 5.4% [95% CI, 4.0%-7.0%] vs 11.0% [95% CI, 6.7%-16.0%] vs 25% [95% CI, 12%-39%], respectively; P < .001). CSCCs with 3 RFs had higher cumulative incidences of local recurrence (1.6-fold), nodal metastasis (1.9-fold), distant metastasis (4.3-fold), and disease-specific death (1.9-fold) compared with those with 2 RFs.Conclusions and RelevanceThe results of this cohort study suggest that the number of RFs is an indicator of risk, and among BWH T2b tumors, those with 3 RFs represent a higher risk subset.
A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
Kudva, Yogish C. , Raghinaru, Dan, Lum, John W. , Graham, Timothy E., Liljenquist, David R., Spanakis, Elias K. , Pasquel, Francisco J. , Ahmann, Andrew , Blevins, Thomas , Kruger, Davida , Brown, Sue A. , Weinstock, Ruth S. , Spaic, Tamara , Hirsch, Irl B., Broyles, Frances E. , Raskin, Philip, Desjardins, Donna, Terry, Adrienne, Singh, Lakshmi G., Davis, Georgia M. , Schmid, Caleb, Kravarusic, Jelena, Coyne, Kasey, Casaubon, Luis, Espinosa, Valerie, Jones, Jaye K., Estrada, Kathleen, Afreen, Samina , Levister, Camilla, O’Malley, Grenye , Liu, Selina , Marks, Sheryl, Peleckis, Amy J. , Tardio, Vanessa , Kurek, Corey, Luker, Ryan, Churchill, Jade, Dean, Ariel, Dennis, Brittany , Fronczyk, Evelyn, Perez, Jennifer, Mukhashen, Shereen, Dhillon, Jasmeen, Ipek, Aslihan, Bzdick, Suzan, Atakov-Castillo, Astrid , Driscoll, Marsha, Averkiou, Xenia, Dalton-Bakes, Cornelia, Moore, Adelyn, Jordan, Lin F., Lesniak, Amanda, Pinsker, Jordan E. , Sasson-Katchalski, Ravid, Campos, Tiffany, Spanbauer, Charles , Kollman, Craig, Beck, Roy W., Rickels, Michael R , Pasqua, Melissa-Rosina , Pinsker, Jordan E , Pasquel, Francisco J , Ahn, David , Aleppo, Grazia , Levy, Carol J. , Steenkamp, Devin W , Rickels, Michael R. , Tsoukas, Michael A. , Hatipoğlu, Betül , Jones, Jaye K., Marks, Sheryl, Tajrishi, Farbod Zahedi , Dean, Ariel, Moore, Adelyn, Lesniak, Amanda, Kanapka, Lauren , Kollman, Craig , Beck, Roy W.

Mayo Clinic

New England Journal of Medicine | March 19, 2025 | Volume: 392 | Issue: 18 | Pages: 1801-1812

10.1056/nejmoa2415948 | PMID 40105270 Get It

Infective endocarditis: it takes a team
Lau, Lawrence , Baddour, Larry M. , Fernández‐Hidalgo, Nuria , Brothers, Thomas D. , Kong, William , Borger, Michael A. , Duval, Xavier, Tribouilloy, Christophe , Golian, Mehrdad , Chan, Kwan L., Prendergast, Bernard , Rubens, Fraser D. , Messika–Zeitoun, David , Baddour, Larry , Prendergast, Bernard D , Messika-Zeitoun, David , Fernández-Hidalgo, Nuria , Duval, Xavier , Obadia, Jean‐François , Corrales‐Medina, Vicente , Auclair, Francois, Mazighi, Mikaël , Habib, Gilbert

Mayo Clinic

European Heart Journal | March 19, 2025 | Volume: 46 | Issue: 24 | Pages: 2275-2288

10.1093/eurheartj/ehaf219 | PMID 40214743 Get It

Abstract Infective endocarditis (IE) is a relatively rare but life-threatening systemic infection, which remains associated with high morbidity and mortality. The epidemiology of IE has shifted to involve an increasing numbers of older patients with both cardiovascular and other types of prosthetic devices, multiple comorbid conditions often requiring invasive procedures, increasingly virulent pathogens, in particular Staphylococcus aureus, or that can harbour anti-microbial resistance, and an escalation of injection drug use in many areas of the world. In parallel, advancements in diagnostic and therapeutic options have led to complex strategies in patients’ management. Despite these epidemiologic shifts, clinical trials have been rare and most of the evidence guiding IE management derives from expert consensus or analysis of large registries. Because of this, a multi-disciplinary IE team-based approach has been recommended as the standard of care. The aim of this review is to explore the rationale for a multi-disciplinary team-based approach to the management of IE. This approach has proved to be potentially beneficial based on multiple investigations that have evaluated patient outcomes. In addition, implementation strategies, feasibility and options of the team approach have also been highlighted.
TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Osterhout, Robin , Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Roscigno, Robert F., Mottola, David, Sitapara, Ravi, Aranda, R., Zisman, Lawrence S. , Bruey, Jean‐Marie, Zamanian, R.T., Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Sitapara, Ravikumar

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804783 Get It

Subgruppenanalyse der Lungenfunktion bei Patientinnen und Patienten mit nicht durch Cystische Fibrose verursachter Bronchiektasen-Erkrankung in der randomisierten, doppleblinden, placebokontrollierten Phase-3-Studie ASPEN
Chalmers, J, Soyza, A De, Haworth, Charles , Mauger, David T. , Loebinger, Michael R. , Hasegawa, Naoki , Aksamit, Timothy R. , Mange, Kevin C., Teper, Ariel, Fernandez, C, Fan, Chuandong , Zhang, X , Metersky, M, Ringshausen, Felix C. , Burgel, Pierre‐Régis , Daley, Charles L. , Soyza, Anthony De , Morimoto, Kozo

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804754 Get It

Subgruppenanalyse der jahrlichen Exazerbationsrate bei Patientinnen und Patienten mit Bronchiektasen-Erkrankung ohne Cystische Fibrose in der randomisierten, doppleblinden, placebokontrollierten Phase-3-Studie ASPEN
Soyza, A De, Haworth, Charles , Mauger, David T. , Loebinger, Michael R. , Aksamit, Timothy R. , Hasegawa, Naoki , Metersky, M, Mange, Kevin C., Teper, Ariel, Fernandez, C, Fan, Chuandong , Zhang, X , Chalmers, J, Ringshausen, Felix C. , Burgel, Pierre‐Régis , Daley, Charles L. , Soyza, Anthony De , Morimoto, Kozo , Fan, C

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804751 Get It

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, R., Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Zamanian, R.T., Cravets, Matt , Roscigno, Robert F., Mottola, David, Parsley, Ed, Aranda, R., Zisman, Lawrence S. , Ghofrani, Hossein Ardeschir , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B, Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612 Get It

Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)
Held, Matthias , Benza, R.L., Channick, Richard, Chin, K. , Frantz, R, Howard, L, McLaughlin, Vallerie V. , Zamanian, R.T., Bruey, Jean‐Marie, Cravets, Matt , Mottola, David, Zisman, Lawrence S. , Parsley, Ed, Roscigno, Robert F., Aranda, R., Vachiéry, J, Sitbon, Olivier , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , McLaughlin, Vallerie V.

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804609 Get It